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Summary The transplantable C57BL/KaLwRij mouse 5T2 multiple myeloma (MM) is a new animal model
for studies on MM in man. Histological examination of the 5T2 MM cells revealed their morphological
heterogeneity. In this study we investigated whether this heterogeneity reflects subpopulations of 5T2 MM
cells with different biological properties. 5T2 MM bone marrow cells were separated according to their
sedimentation velocity (s.v.). When intravenously injected into syngeneic recipient mice, cells with s.v. of
8mmh-1 led to the development of detectable 5T2 MM after 6 weeks; in contrast, 18 weeks elapsed before
the same result was achieved with cells of s.v. lower than 5mmh-1. Flow cytometric analysis revealed that
5T2 MM cells had an aneuploid DNA content and that most cycling 5T2 MM cells were large, their s.v. rate
exceeding 9mmh-1. It was further demonstrated that about half of all aneuploid cells carried on their
membrane the 5T2 MM idiotype. The majority of the idiotype-positive cells had s.v. rate exceeding
6.5mmh-1 (16%-39%) or lower than 3mmh-1 (16%-19%). The 5T2 MM was shown to contain
subpopulations of cells of different size, proliferation capacity and expression of their membrane 5T2
idiotype; this, most likely reflects cells in different stages of differentiation. The mouse 5T2 MM corresponds
also in this respect with MM in man.
Multiple myeloma (MM) is generally regarded as a malig-
nant monoclonal proliferative disorder of immunoglobulin
(Ig)-secreting plasma cells predominantly located in the bone
marrow (BM). However, there is increasing evidence that less
differentiated B-cells are also part of the myeloma cell clone.
Neoplastic cells of transplanted murine plasmacytomas have
been demonstrated to differentiate from small non-secreting
clonogenic cells to large plasmacytoid cells secreting the
homogenous Ig (Rohrer et al., 1977; Daley, 1981). In man,
precursor cells expressing the myeloma idiotype in various
stage of differentiation were demonstrated in the peripheral
blood and in the BM (reviewed in Mellstedt et al., 1982;
Mellstedt et al., 1984; Lokhorst et al., 1985). These findings
suggested that the malignant transformation leading to the
development of MM already occurred in a precursor of the
plasma cell. Further support for this hypothesis was offered
by the observation of chromosomal abnormalities in plasma
cells as well as in cells with a B-lymphocyte phenotype of a
patient with plasma cell leukaemia (MacKenzie et al., 1985).
These chromosomal abnormalities showed a similarity with
those reported in cases of MM. However, functional proof
ofthe participation ofidiotype-bearing B-cells in the myeloma
clone has not yet been achieved. In vitro stimulation of
idiotype-bearing B-cells in the presence of mitogens such as
pokeweed mitogen or Staphylococcus aureus did not lead
to a subsequent differentiation of these cells into a more
mature Ig-secreting phenotype (Peest et al., 1984; Bloem,
1985). Moreover, it had been suggested by other investi-
gators that the idiotype-bearing lymphocytes in MM were in
fact T-lymphocytes binding the myeloma-Ig by Fc-receptors
with specificity for its isotype (Hoover et al., 1981). Recently,
myeloma precursors of lymphoid morphology that lacked
surface and cytoplasmic Ig, but expressed the acute lympho-
blastic leukaemia antigen (CALLA) were identified in the
BM of patients with MM. In vitro stimulation of these cells
with the phorbol ester 12-0-tetradecanoyl-phorbol-13 acetate
(TPA) resulted in their transformation into plasma cells that
synthesized the myeloma-specific Ig (Caligaris-Cappio et al.,
1985). This observation indicated the existence of a func-
tional relationship between more differentiated MM-cells and
their precursors. However, the exact role of the idiotype-
bearing B-lymphocyte has not become clear in that study.
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A suitable experimental animal model for MM is a
prerequisite for detailed studies on the basic biological
mechanisms of this neoplasm. Recently, spontaneous
multiple myeloma developing in a number of aging
C57BL/KaLwRij mice has been observed (Radl et al.,
1985a). This mouse MM resembles the human disease in
several respects. In contrast with the induced mouse plasma-
cytomas, it is of spontaneous origin and the MM cells are
predominantly located in the BM; a circulating monoclonal
myeloma protein reflects the extent of the tumour load, and,
in many cases, the MM is complicated by severe osteolytic
bone destruction (Radl et al., 1985a). Among the different
established transplantable ST MM lines, the 5T2 MM has
been studied most extensively (Radl et al., 1985b). Examin-
ation of the 5T2 MM BM cells by light microscopy revealed
that these cells were heterogeneous in morphology and,
especially, in size. Therefore, the 5T2 MM population was
suspected to contain cells in different stages of maturation.
The aim of the present study is to extend the histologically
established heterogeneity of the 5T2 MM cells to other
markers such as growth potential in vivo, nuclear DNA
content, and expression of the 5T2 MM-idiotype. For this
purpose, subsets of 5T2 MM cells were obtained by fraction-
ation of BM cells from 5T2 MM-bearing mice according to
their size by velocity sedimentation. The results of this study
indicate that the 5T2 MM consists of cells in various stages
of differentiation. This mouse MM offers a useful experi-
mental model for further studies, among others, on the
phenotype of the clonogenic cell of this malignancy.
Materials and methods
Mice
Male and female C57BL/KaLwRij mice from the colony of
the TNO Institute for Experimental Gerontology were used
in all experiments. They were maintained under conventional
conditions. Detailed information on husbandry, health
status, survival data, and age-associated pathology of this
strain has been published elsewhere (Van Zwieten et al.,
1981).
5T2 MM line
The 5T2 MM originated spontaneously in an aging
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C57BL/KaLwRij mouse (Radl et al., 1979). This MM has
since been propagated by i.v. transfer of BM or spleen cells
into young recipients of the same strain. The 5T2 MM used
for this study was in its 22nd transplantation generation.
The development of the 5T2 MM in the recipient mice was
monitored by determinations of the 5T2 MM protein
(IgG2a-kappa) in serum samples by double immunodiffusion
technique according to Ouchterlony, taking advantage of the
antigen specificity of this MM protein for dinitrophenyl-
conjugates (Croese et al., 1985).
Cell suspensions
Mice were sacrificed by exsanguination under ether
anaesthesia. BM cells were flushed from the femurs, tibiae,
and humeri of the mice and suspended in Hank's minimal
essential medium (Gibco, Paisley, Scotland) supplemented
with 15mM HEPES (Flow Laboratory, Irvine, Scotland)
(pH =7.1, osmolarity=310mOsm). The cells were washed 2
times in the same medium. They were subsequently re-
suspended in Hank's balanced salt solution (HBSS) (Gibco,
Paisley, Scotland) (pH=7.1, osmolarity=310 mOsm).
Viability of the 5T2 MM BM cells was determined by trypan
blue exclusion. All manipulations with cells were performed
at a temperature of40C.
Cellfractionation
5T2 MM BM cels were separated on the basis of differences
in their sedimentation velocity according to Miller (Miller,
1984). Briefly: 5T2 MM BM cells were suspended in HBSS
supplemented with 0.35% bovine serum albumin (BSA) and
loaded as a thin layer on top of a HBSS column; this
column was supplemented with a shallow density gradient
ranging from 0.5 to 2% BSA in order to stabilize the fluid
column for the prevention of turbulence and convection
mixing during loading and sedimentation. The cells were
allowed to sediment under the influence of gravity for 3h
and collected in fractions of equal volume. The number of
nucleated cells within the 5T2 MM BM cell suspension and
within each fraction was determined with an electronic
cytometer (Elzone, Elmhurst, Ill., USA). Aliquots of cells
were taken from the unseparated 5T2 MM BM suspension
and from each fraction, and resuspended in HBSS sup-
plemented with 0.1% BSA and 0.1% sodium azide
(HBSS/BSA/Azide) for analysis of the surface membrane
5T2 MM-idiotype expression and of the nuclear content of
DNA.
cells stained with FITC-conjugates were analysed in a fluor-
escence activated cell sorter (FACS II, Becton and
Dickinson, Mountain View, Ca., USA) equipped with
logarithmic amplifiers (Visser et al., 1980; Boersma et al.,
1985).
Preparation ofcellsfor morphological examination
Glass slides with cells from the different fractions were
prepared using a cytospin centrifuge (Hijmans et al., 1969).
The cell preparations were stained with May-Grunwald-
Giemsa and examined by light microscopy.
Analysis ofcellular DNA content
DNA of unfractionated 5T2 MM BM cells as well as of cells
from each fraction was stained with propidium iodide (PI)
(Calbiochem, San Diego, Ca., USA) according to Taylor
(1980): 106 cells suspended in 50pl of HBSS/BSA/Azide were
incubated with 750M1 of a solution of the same medium
containing 50ygml-1 PI and 1% Triton X-100 (Sigma
Chem. Co., St. Louis, Mo., USA) for 20min at room
temperature. Analysis of the PI-fluorescence intensity of the
stained cells was performed with the FACS II using linear
amplification of the signals.
Results
Two peaks were observed in the distribution curve of the
5T2 MM BM cells according to their sedimentation velocity
(Figure 1). The first peak contained cells with a sed. rate of
3 to 5mmh-1; the second peak consisted of larger cells with
a sed. rate of 6mmh-1. A relatively high proportion of all
cells sedimented with a velocity of >6mmh-1.
All mice injected i.v. with unfractionated 5T2 MM BM
cells showed the development of 5T2 MM after 12 weeks, as
demonstrated by the presence of 5T2 MM protein in their
sera. A more rapid development of 5T2 MM was observed
in mice which received cells from fractions with a sed. rate of
8mmh-1. 5T2 MM-protein was detected in the sera of
these recipients already at 6 weeks after transplantation. In
contrast, 5T2 MM-protein was detectable in the sera from
mice transplanted with the smaller cells (sed. rate
<5mmh-1) only after 18 weeks (Figure 2).
Twenty-three percent of the cells within the unfractionated
5T2 MM BM expressed the 5T2 MM-idiotype on their
Transplantation
Cells from the unfractionated 5T2 MM BM and from
selected fractions were resuspended in HBSS and injected i.v.
into young syngeneic recipient mice. Each mouse received
0.5 x 106 cells. The development of the 5T2 MM was weekly
monitored in serum samples from all recipients. The included
experimental groups each consisted of 4 recipients.
Immunofluorescence
Expression of the 5T2 MM-idiotype on the surface
membrane of the unseparated 5T2 MM BM cells and on the
cells within the different fractions was determined by a
monoclonal antibody (MAB) (clone 145-4.1 of IgGI isotype)
to this idiotype (Croese et al., 1985). For this purpose, 50,ul
of a suspension containing 106 cells was incubated for 30min
with 50u1 of an appropriate dilution of unconjugated MAB
145-4.1 followed by a second incubation for 30min with
50p1 of a FITC-conjugated goat anti-mouse IgGI antibody
(Nordic Immunological Lab., Tilburg, The Netherlands). All
antibodies were centrifuged before use at maximum speed for
10min in a Beckman Airfuge (Beckman Instrumentals b.v.,
Mijdrecht, the Netherlands) to remove aggregated material.
The cells were washed after each incubation, and they were
suspended in HBSS/BSA/Azide after the completion of the
staining-procedure. Immunofluorescence distributions of the
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Figure 1 Distribution of 5T2 MM BM cells according to their
sedimentation velocity. The cells were sedimented at 1 g for 3h at
4°C. The proportion of cells in each fraction is expressed as a
percentage of the number of cells in the peak fraction. The
largest fractions were found at sedimentation rates of 3 to 5 and
6mmh-1.
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Figure 2 Distribution of cells which caused the development of
5T2 MM according to their sed. rate. Mice of the experimental
groups (n =4) were each injected i.v. with 0.5 x 106 cells from one
of the different fractions of 5T2 MM BM cells obtained by
velocity sedimentation. The percentage of recipients developing
5T2 MM is shown at 6, 12, and 18 weeks from the day of
transplantation. In each figure, the total 5T2 MM BM sedi-
mentation profile is indicated (full continuous line).
Mice which received cells with a sedimentation rate of
-8mmh-' developed a detectable MM already at 6 weeks after
transplantation. In contrast, transplantation of cells with a
sedimentation rate <5mmh-1 resulted in the development of
5T2 MM only after 18 weeks.
surface membrane. After separation of the 5T2 MM BM
suspension, the highest proportion (16-39%) of surface
membrane 5T2 MM-idiotype-positive cells was present
within the fractions containing the larger cells, i.e., the cells
with a sed. rate exceeding 6.5mmh-1. The fractions with the
smallest cells (sed. rate <3 mmh-1) contained a higher
percentage (16-19%) of 5T2 MM-idiotype-positive cells than
the fractions with cells of intermediate size (sed. rate between
3 and 6mmh-1) (6-12%) (Figure 3).
Three distinct peaks were present in the distribution
pattern of the DNA content of unfractionated 5T2 MM BM
cells (Figure 4): two peaks representing the majority of the
cells and a small third one. The cells within the first peak
expressed the same fluorescence intensity as the non-cycling
cells (in GO/GI phase) of normal BM (=2n). The second
peak was located at
- 1.75 times the fluorescence intensity of
the first one (=3.5 n). The position of this peak in the DNA-
distribution curve corresponded with that of the cycling cells
in the late S-phase in the DNA-distribution curve of normal
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Figure 3 Distribution of surface membrane 5T2 MM-idiotype-
positive cells in individual fractions according to their sedi-
mentation rate. The sedimentation velocity profile of unfraction-
ated 5T2 MM BM cells is indicated (full continuous line).
The cells were stained by a monoclonal anti-5T2 MM-idiotype
antibody of IgGl isotype (145-4.1) and a FITC-conjugated goat
anti-mouse IgGl reagent. The surface membrane 5T2 MM-
idiotype expression was determined by FACS-analysis using
logarithmic amplification. The highest percentages of 5T2 MM-
idiotype-positive cells were found in the fractions of cells with a
sedimentation rate exceeding 6.5mmh-1. Non-fractionated 5T2
MM BM contained 23% of 5T2 MM-idiotype-positive cells.
BM. The third peak was located at 2 times the fluorescence
intensity of the second peak (7n). Individual cell fractions
obtained by the velocity sedimentation procedure contained
different numbers of cells with DNA contents of 3.5n and
7n. Within the fractions with larger cells (sed. rate exceeding
6mmh-1), an increase in the proportion of cells with a
DNA content of 3.5n was observed as compared with the
unseparated 5T2 MM BM cells and with the fractions
containing cells with sed. rates <6mmh-1 (Figure 5). An
increase in the proportion of cells with a DNA content of
3.5n was also observed in the fractions with a sed. rate of
3mmh-1 (Figure 5). A distinct third peak, representing
the cells with 7n DNA, was only observed in the DNA-
distribution curves of the fractions containing cells with sed.
rates exceeding 9mmh 1, i.e., the largest cells (Figure 5).
Discussion
The 5T2 MM is one of the mouse MMs which originated
spontaneously in aging C57BL/KaLwRij mice (Radl et al.,
1985a). It is a suitable experimental model for studies on the
nature of this malignancy. In this study, it was determined
whether the morphological heterogeneity of the 5T2 MM
cells as observed by histology (Radl et al., 1985b and
unpublished observations) reflected the existence of different
subpopulations within this neoplasm.
A large number of cells had to be processed because the
tumorigenic potential of cells from individual fractions was
tested by transplantation in vivo. For this reason, the velocity
sedimentation procedure was chosen for fractionation of 5T2
MM BM. Cells in normal BM with sed. rates of 3mmh-1
and 5mmh-1 have been reported to be lymphoid cells and
myeloid cells respectively (Visser et al., 1980; Miller, 1984).
The relatively high proportion of cells with a sed. rate
exceeding 6mmh-1 which were obtained after velocity sedi-
mentation of the 5T2 MM BM cell population reflected the
presence of large abnormal myeloma cells.
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Figure 4 DNA-histogram of 5T2 MM BM cells. The nuclear
DNA was stained with PI and the fluorescence intensity was
determined by analysis in the FACS II using linear amplification
of the signals. The DNA-distribution of normal mouse BM cells
is shown for comparison.
The first peak in the 5T2 MM BM DNA-distribution curve
corresponds with non-cycling normal BM cells; the second peak
is located at about 1.75 times the fluorescence intensity of the
first one, and the third peak represents cells with twice the
fluorescence intensity of the second peak.
A number of at least 104 events (cells) was analysed for the
determination of each DNA-histogram.
Intravenous transfer of cells from fractions with sed. rates
of a very broad range (from 3 to
- 11 mmh -1) into
syngeneic recipient mice resulted in the development of 5T2
MM. However, 5T2 MM BM cells with a sed. rate of
8mmh-1 required a shorter period of time to develop into
an overt myeloma as compared with the unfractionated 5T2
MM BM cells or cells from the other fractions. This
indicated that the fractions containing cells with a sed. rate
of 8 mmh-' included more of the cycling tumour cells than
the other fractions. The increase in time interval between
transplantation of the smaller cells (sed. rate between 3 and
5mmh-1) and development of the 5T2 MM might be
explained by the assumption that these cells were 5T2 MM
cells in an earlier stage of differentiation. The small cells
apparently differentiated into a more mature stage before
they began to proliferate. Contamination of the fractions
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Figure 5 Distribution of all 5T2 MM cells (A) and of cycling
5T2 MM cells (-) according to their DNA content within
fractions obtained by velocity sedimentation.
All 5T2 MM cells were calculated as the proportion of cells
with a DNA content exceeding 2n minus the proportion of
cycling non-myeloma BM cells. The latter proportion was calcu-
lated by assuming that the proportion of cycling normal BM
cells in 5T2 MM BM and in normal mouse BM was identical.
The 5T2 MM cells with a DNA content exceeding 3.5n were
assumed to reflect the cycling 5T2 MM cells in S/G2/M phase.
The sedimentation velocity profile of total 5T2 MM BM cells
is indicated (full continuous line).
containing the smaller cells with large cells cannot be totally
excluded. However, this is unlikely because corresponding
results were obtained in three different experiments. Further-
more, examination of the cells in the different fractions by
light microscopy revealed a plasmacytoid appearance of the
cells from the fractions with a moderate to high sed. rate,
whereas the slower sedimenting cells had a lymphoid
morphology.
The distribution curve of the DNA content of 5T2 MM
cells demonstrated the presence of aneuploid cells. Abnor-
malities in DNA content of human myeloma cells have been
demonstrated by several investigators (Latreille et al., 1980;
Barlogie et al., 1982; Montecucco et al., 1984). An excellent
correlation between the percentage of cells with an abnormal
DNA content and the proportion of identifiable plasma cells
in the bone marrow of MM patients has been reported
(Latreille et al., 1980). The investigators concluded that
cellular DNA content is a useful marker for estimation of
the myeloma cell mass. In the human situation, the focal
distribution of the myeloma cells within the BM compart-
ment complicates a reliable assessment of the percentage of
tumour cells by DNA-distribution analysis of the BM cells
from BM aspirates or biopsies. A high proportion of the
total BM compartment of 5T2 MM-bearing mice is,
however, available for processing, thereby increasing the
chance for an accurate determination of the percentage of
aneuploid cells. The cells with a DNA content of 2n and 4n
in the 5T2 MM BM population were assumed to be normal
BM cells in, respectively, the GO/Gl- and G2/M-phase of the
cell cycle. The aneuploid cells containing 3.5n and 7n DNA
were considered to be, respectively, the non-cycling and
cycling (G2/M-phase) myeloma cells (with the exception of
the cycling cells with a normal DNA content in the S-phase
which also contain - 3.5n DNA). The aneuploid cells with a
DNA content between 3.5n and 7n were regarded as being
the 5T2 MM cells in the S-phase of the cell cycle. The DNA-
distribution pattern of BM cells from a 5T2 MM-bearing
mouse was compared with that of normal mouse BM cells in
order to determine the percentage of 5T2 MM cells within
the entire 5T2 MM BM cell population. The ratio between
5T2 total
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cycling and non-cycling cells with a normal DNA content
from the 5T2 MM BM was tentatively assumed to corres-
pond with the ratio between cycling cells and non-cycling
cells from normal BM. This assumption made it possible to
estimate the percentage of cycling non-myeloma cells within
the unfractionated 5T2 MM BM and within the different
fractions. The percentage of 5T2 MM cells was calculated by
subtracting the percentage of cycling non-tumour cells from
the percentage of cells with a DNA content exceeding 2n.
Based on DNA-distribution analysis, a substantial increase
in the percentage of 5T2 MM cells was observed in the
fractions with sed. rates between 6 and 11 mmh-1 when
compared with the proportion of 5T2 MM cells in un-
fractionated 5T2 MM BM. This supports the hypothesis that
the high proportion of large cells in the 5T2 MM BM
reflects mainly the presence of the myeloma cells. In
addition, the observation that i.v. transplantation of cells
from the large cell fractions into syngeneic recipient mice
resulted in the development of a myeloma after a relatively
short time interval is in agreement with the finding that a
high percentage of proliferating 5T2 MM cells (7n DNA)
was present within these fractions. However, the first 5T2
MMs were detected in recipient mice transplanted with cells
from fractions with sed. rates between 8 and 9mmh-1.
These fractions contained a lower percentage of cells with a
7 n DNA content than those with sed. rates exceeding
9mmh-1. An explanation for this lack of correlation
between the maximum percentage of 7n DNA containing
cells and the maximum rate of development of 5T2 MM
may be that part of these cells in the fractions with sed. rates
of more than 9mm h 1 were double nucleated 5T2 MM cells
which were actually not in cycle.
The unfractionated 5T2 MM BM cell population con-
tained about 20% of surface membrane 5T2 MM-idiotype-
positive cells. Nearly 40% of the unfractionated 5T2 MM
BM cells were considered to belong to the myeloma clone on
the basis of their aneuploidy. This indicates that only half of
these cells expressed the 5T2 MM-idiotype on their surface.
The hypothesis that the heterogeneity of the 5T2 MM cell
population is at least in part a reflection of differences in
maturity of the myeloma cells is supported by the variety in
the percentages of surface 5T2 MM-idiotype-positive cells in
the different fractions. Matured plasma cells do not bear Ig-
molecules on their surface membrane (Mellstedt et al., 1984).
The idiotype-positive cells of the large cell fractions might
have a plasmablastic phenotype.
It may be concluded that small 5T2 MM cells (sed.
rates between 2.5 and 3.5mmh-1) are less mature, non-
proliferating myeloma cells, presumably of the B-lymphocyte
phenotype. This is supported by the following observations:
(a) typical myeloma cells are in general of larger size than
precursor cells of the B-cell lineage, i.e., the immature and
mature B-lymphocytes (Daley, 1981); (b) the increase in
proportion of tumour cells within the small cell fractions
paralleled to a certain degree the increase in proportion of
surface membrane 5T2 MM-idiotype-positive cells in these
fractions. This finding probably represented an increase in
the percentage of 5T2 MM-idiotype bearing B-lymphocytes;
(c) a substantial number of cycling cells containing 7n DNA
was not present within the small cell fractions. The
conclusions of several investigators that precursor cells
belong to the neoplastic clone in the mouse plasmacytoma
and human MM are in agreement with the findings in this
study (Rohrer et al., 1977; Daley, 1981; Mellstedt et al.,
1982, 1984; Lokhorst et al., 1985).
In conclusion, the morphological heterogeneity of the 5T2
MM BM cell population reflects the existence of subsets of
5T2 MM cells in different stages of differentiation. The 5T2
MM model corresponds also in this respect with MM in
man. Further studies are necessary to more precisely
characterize the different precursor cells in order to define
the clonogenic cell of this malignancy.
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